Verition Fund Management LLC Buys 43,447 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Verition Fund Management LLC raised its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 180.6% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 67,502 shares of the biopharmaceutical company's stock after buying an additional 43,447 shares during the quarter. Verition Fund Management LLC owned 0.06% of Catalyst Pharmaceuticals worth $1,342,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the business. GAMMA Investing LLC raised its holdings in shares of Catalyst Pharmaceuticals by 62.1% in the third quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company's stock valued at $35,000 after buying an additional 681 shares during the last quarter. nVerses Capital LLC acquired a new stake in Catalyst Pharmaceuticals in the 3rd quarter valued at about $50,000. Larson Financial Group LLC raised its stake in shares of Catalyst Pharmaceuticals by 27,218.2% in the third quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company's stock worth $60,000 after acquiring an additional 2,994 shares during the last quarter. CWM LLC lifted its position in shares of Catalyst Pharmaceuticals by 686.5% during the second quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company's stock worth $63,000 after purchasing an additional 3,549 shares in the last quarter. Finally, Meeder Asset Management Inc. acquired a new position in shares of Catalyst Pharmaceuticals during the second quarter worth approximately $70,000. 79.22% of the stock is owned by institutional investors.

Catalyst Pharmaceuticals Price Performance

Catalyst Pharmaceuticals stock traded up $0.32 during midday trading on Friday, hitting $22.02. The company's stock had a trading volume of 536,075 shares, compared to its average volume of 1,102,031. The company has a market cap of $2.63 billion, a price-to-earnings ratio of 18.66, a PEG ratio of 3.35 and a beta of 0.75. The company has a 50-day moving average price of $21.45 and a two-hundred day moving average price of $18.96. Catalyst Pharmaceuticals, Inc. has a 1-year low of $13.00 and a 1-year high of $24.27.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, Director Molly Harper sold 17,500 shares of the company's stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $22.00, for a total value of $385,000.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Gary Ingenito sold 12,000 shares of the stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $22.72, for a total transaction of $272,640.00. Following the sale, the insider now directly owns 51,391 shares of the company's stock, valued at $1,167,603.52. This represents a 18.93 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 11.00% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on CPRX. Truist Financial increased their price target on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a "buy" rating in a research note on Monday, November 11th. HC Wainwright restated a "buy" rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday, November 8th. Finally, Stephens assumed coverage on Catalyst Pharmaceuticals in a report on Monday, November 18th. They set an "overweight" rating and a $35.00 price objective on the stock. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Catalyst Pharmaceuticals has an average rating of "Buy" and an average target price of $31.14.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.